Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Autor:
W.S. Fred Wong, Xinni Xu, W.S. Daniel Tan, Nadia Suray Tan, Veronique Angeli, Mei Fong Liew, Yuansheng Melvin Sng, Parameswaran Nair, Siew Shuen Chao, Hui Fang Lim, Yew Kwang Ong, De Yun Wang, Manali Mukherjee
Publikováno v:
Airway pharmacology and treatment.
Background: In severe eosinophilic asthma (SEA), mepolizumab, an anti-interleukin 5 (IL-5) monoclonal antibody (mAb) can reduce asthma exacerbations and oral corticosteroid (OCS) requirements, but effect on nasal polyps (NP) recurrence and need for s
Autor:
Aikaterini Detoraki, Giuseppe Quaremba, Raffaella Giacco, Cecilia Calabrese, Matilde Boccia, Mauro Maniscalco, Eugenio Tremante, Giuseppe Spadaro, Maria D'Amato, Remo Poto
Publikováno v:
Airway pharmacology and treatment.
Background: Eosinophilic severe asthma is frequently associated to chronic rhinosinusitis and nasal polyposis (CRSwNP), which contributes to the poor asthma control in these patients. Mepolizumab is an anti-IL-5 monoclonal antibody, which has been re
Publikováno v:
Airway pharmacology and treatment.
Allergic bronchopulmonary aspergillosis (ABPA) is a severe hypersensitivity reaction to aspergillus species colonizing the airways of patients with asthma or cystic fibrosis. Biologicals including anti-IgE and anti-IL-5 antibiodies have strongly chan
Autor:
Alexis Pulga, Morten Hvidtfeldt, Caroline Sanden, Jonas S. Erjefält, Nielsen Ole, Morten Hostrup, Carl-Magnus Clausson, Daisy Bornesund, Celeste Porsbjerg, Asger Sverrild
Publikováno v:
Airway pharmacology and treatment.
Background: The effect of inhaled corticosteroids (ICS) in patients with type 2 low (T2-low) asthma is unpredictable. Biomarkers are lacking to identify patients likely to benefit from ICS. We speculate that airway hyperresponsiveness (AHR) to mannit
Publikováno v:
Airway pharmacology and treatment.
Allergic bronchopulmonary aspergillosis (ABPA) often complicates severe asthma (SA). Omalizumab (OMA) has been successfully employed in the treatment of ABPA, in addition to systemic corticosteroids and itraconazole. We report two cases of patients w
Autor:
Lorena Garcia Conde, Jorge Maspero, Agustín Sojo, Pritam Gupta, Matthias Krüll, Richard N. van Zyl-Smit, Oliver Kornmann, Anna Salina, Christian Gessner
Publikováno v:
Airway pharmacology and treatment.
Aim: Prior studies have confirmed the fast and sustained bronchodilation with IND and GLY1, and improved lung function with MF2. Here we evaluated the effect of IND/GLY/MF fixed-dose combination via Breezhaler® vs Sal/Flu+Tio on symptoms and rescue
Autor:
Santiago Quirce Gancedo, Montserrat Puntes Rodríguez, Teresa Bigorra Rodríguez, Julio Castro Palomino Laria, Eder Fredy Mateus Medina, Rosa M. Antonijoan Arbos, Ignasi Gich Saladich, Nahomi Castro Palomino Laria, David Ramos-Barbón, Nadia S. Brienza
Publikováno v:
Airway pharmacology and treatment.
Background: PBF-680 is an oral A1 adenosine receptor antagonist in development for asthma. Aims and Objectives: To evaluate PBF-680 efficacy to inhibit the LAR, a standard goal for asthma therapies development. Methods: Double-blind, randomized, cros
Autor:
Claus Bachert, Stella E. Lee, Martin Wagenmann, Wytske Fokkens, Claire Hopkins, Steven G. Smith, Joseph K. Han, Robert Chan, Ana E. Sousa, Neil R.W. Martin, Bhabita Mayer, Martin Desrosiers
Publikováno v:
Airway pharmacology and treatment.
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease with recalcitrant symptoms. NP tissue eosinophils lead to recurrence, which often require repeat surgeries.1 Aims: To assess the efficacy and safety of 4-weekly
Autor:
Peter D'Andrea, Motoi Hosoe, Ana-Maria Tanase, Kenneth R. Chapman, Abhijit Pethe, Devendra Jain, Huib A. M. Kerstjens, Konstantinos Kostikas
Publikováno v:
Airway pharmacology and treatment.
Aim: This post hoc analysis from the IRIDIUM study (NCT02571777) assessed reduction in exacerbations with indacaterol/glycopyrronium/mometasone (IND/GLY/MF) high-dose MF vs medium-dose MF in patients with inadequately controlled asthma. Methods: This
Autor:
Xin Lu, Heribert Staudinger, Pierluigi Paggiaro, G. Walter Canonica, Nikhil Amin, M. Zhang, Leda Mannent, Neil M.H. Graham, Jorge Maspero, Martin Desrosiers, Seong H. Cho, Joseph K. Han, Naimish Patel, Tanya M. Laidlaw, Peter Hellings, Claus Bachert, Joaquim Mullol, Claire Hopkins
Publikováno v:
Airway pharmacology and treatment.
Introduction: CRSwNP patients (pts) with NSAID-ERD often have more severe disease than non–NSAID‑ERD pts. DPL, a fully human mAb, blocks the shared receptor component for IL-4/IL-13, key drivers of type 2 inflammation. Aim: To assess DPL treatmen